Abbott Labs: A Dividend King on Sale? Why Long-Term Investors Are Eyeing the Dip
Despite a post-earnings slump and near 52-week lows, Abbott Laboratories' resilient medical device unit, strategic expansion in diabetes care, and a landmark acquisition in cancer diagnostics paint a promising long-term picture for this Dividend Aristocrat.